CD24 Expression Is Increased in 5-Fluorouracil-Treated Esophageal Adenocarcinoma Cells

• Published in: Frontiers in pharmacology 2017-05, Vol.8, p.321-321
• Main Authors: Jiménez, Pilar, Chueca, Eduardo, Arruebo, María, Strunk, Mark, Solanas, Estela, Serrano, Trinidad, García-González, María A, Lanas, Ángel
• Format: Article
• Language: English
• Subjects: 5-fluorouracil; cancer stem cells; CD24; celecoxib; esophageal adenocarcinoma; Pharmacology
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2017.00321

The cancer stem cell (CSC) model suggests that there are subsets of cells within a tumor with increased proliferation and self-renewal capacity, which play a key role in therapeutic resistance. The importance of cyclooxygenase-2 ( ) in carcinogenesis has been previously established and the use of inhibitors as celecoxib has been shown to exert antitumor effects. The present study investigated whether treatment of esophageal adenocarcinoma (EAC) cells with 5-fluorouracil (5-FU) or the growth of tumor spheres increased the proportion of CSCs and also if treatment with celecoxib was able to reduce the putative CSC markers in this tumor. OE19 and OE33 EAC cells surviving 5-FU exposure exhibited an increase in CSC markers and and also an increased resistance to apoptosis. EAC cell lines had the capacity to form multiple spheres displaying typical CSC functionalities such as self-renewal and increased levels. In addition, after the induction of differentiation, cancer cells reached levels of similar to those observed in the parental cells. Treatment with celecoxib alone or in combination with 5-FU also resulted in a reduction of expression. Moreover, celecoxib inhibited the growth of tumor spheres. These findings showing a reduction in CSC markers induced by celecoxib suggest that the inhibitor might be a candidate for combined chemotherapy in the treatment of EAC. However, additional clinical and experimental studies are needed.